TransCon hGH
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency, Pediatric
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Trial Timeline
Dec 19, 2017 → Feb 21, 2023
NCT ID
NCT03344458About TransCon hGH
TransCon hGH is a phase 3 stage product being developed by Ascendis Pharma for Growth Hormone Deficiency, Pediatric. The current trial status is completed. This product is registered under clinical trial identifier NCT03344458. Target conditions include Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03344458 | Phase 3 | Completed |
| NCT03305016 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency, Pediatric